TELA

TELA Bio, Inc. (TELA) ESG Analysis Analysis (2026)

Invetso Score: 6/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Environmental

Score: 5.8 (Moderate)

TELA’s R&D intensity supports product innovation with limited direct environmental burden, but peers in medtech often disclose more formal climate and resource-management programs.

The company’s capital-light profile likely reduces manufacturing emissions exposure versus vertically integrated peers, yet the absence of disclosed environmental targets limits relative strength.

No material environmental controversies are provided, but limited evidence of emissions, waste, or supply-chain stewardship disclosure keeps positioning below stronger peer reporters.

Compared with larger healthcare technology peers, TELA appears less exposed to heavy industrial environmental risk, though its ESG disclosure depth remains comparatively thin.

Social

Score:

TELA’s R&D-to-revenue mix suggests product development capability that can support patient-focused innovation, but peers typically provide clearer evidence on clinical and access outcomes.

Stock-based compensation remains modest relative to revenue, which can indicate less dilution pressure on employees, though it does not by itself establish superior labor practices.

No workforce, safety, or product-responsibility controversies are provided, but the lack of disclosed social metrics limits confidence versus better-reporting medtech peers.

Relative to peers, TELA appears operationally stable on social risk, yet it trails stronger issuers that publish more comprehensive human-capital and product-safety disclosures.

Governance

Score:

Low stock-based compensation relative to revenue suggests comparatively restrained equity dilution, but peers with stronger governance often pair this with broader incentive transparency.

Negative leverage metrics indicate limited balance-sheet stress, which can reduce governance pressure, though they do not substitute for board or shareholder-rights disclosure.

No governance controversies are provided, but the absence of board independence, audit, and executive-pay detail keeps relative governance positioning only average.

Compared with peers, TELA appears free of obvious governance red flags, yet its disclosed governance framework is not strong enough to rank above better-governed issuers.

Overall Score

Score:

TELA’s ESG profile is broadly average versus peers, with limited disclosed controversies and modest capital discipline offset by thin sustainability and governance disclosure.

Score Driver: Limited ESG Disclosure Depth Relative To Peers

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on TELA Bio, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →